Clinical trial NCT03944499: Phase 1 Study of FS-1502 in Patients With HER2 Expressed Advanced Solid Tumors and Breast Cancer.
Official title: A Phase I,Multicenter,Open-label,Single-arm Study:A Dose-escalation Phase Evaluating FS1502 in Patients With HER2 Expressed Advanced Solid Tumors,and a Dose-expanded Phase in Patients With Local Advanced or Metastatic,HER2+ Breast Cancer
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE1
Conditions: Solid Tumor
Breast Cancer
Lead sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Sponsor class: INDUSTRY
First posted: 2019-05-09
Enrollment: 297
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The study comprises two phases: Phase 1a and Phase 1b. The purpose of the study is to observe the safety， tolerability and efficacy of FS-1502.

Detailed description: The study is designed as an open label, single arm, Phase 1a/1b study with a dose-escalation phase to evaluate FS-1502 in patients with HER2 expressed advanced malignant solid tumors (phase 1a) and an expanded cohort (phase 1b) to evaluate FS-1502 in patients with metastatic, HER2-positive breast cancer. The primary aim of the phase 1a portion of this study is to determine the safety and tolerability of FS-1502. The primary aim of the phase 1b portion is to demonstrate efficacy.

Eligibility criteria: Inclusion Criteria:

1. Age ≥18 years at the time of study registration (men and women eligible);
2. Phase Ia dose-escalation study:

   Patients with HER2-expressing advanced malignant solid tumors who had failed to standard therapy(including surgery, chemotherapy, radiation therapy or biotherapy) , or can not receive standard therapy, or no standard therapy is available.
   1. HER2 expression: IHC3+, IHC2+/FISH+
   2. HER2 expression: IHC1+, IHC2+/FISH-

   Phase Ib dose-expanded study:

   Histologically or cytologically confirmed HER2-positive patients with advanced breast cancer who had previously received at least 2 line therapy and had failed anti-HER2 therapy. Details as follows:
   1. HER2 positive (defined as IHC3+ or IHC2+/FISH+);
   2. For patients with advanced breast cancer who had previously failed anti-HER2 therapy and had received at least 2-line therapy, postoperative adjuvant therapy which could be considered as a treatment line number if disease progression during treatment and within 12 months after completion of treatment.
   3. Provide evidence of disease progression or intolerable toxicity as confirmed by the investigator or medical history recorded prior to enrollment.
   4. The enrollment can be based on written HER2 test report from certified local lab, and if patients had no HER2 test report, they should provide sufficient paraffin sections or fresh tumor tissue specimens which should be sent to the local lab or the central laboratory for testing and confirmation.

   Pivotal clinical study:

   Patients with locally advanced or relapsed metastatic breast cancer who have been histologically or cytologically confirmed to be HER2-positive and who have received two or more lines of anti-HER2 therapy in the past. Details as follows:
   1. Her2-positive patients: Patients with IHC3+ or IHC2+ and FISH positive patients should provide enough tumor tissue samples within 5 years for the central laboratory to confirm HER2 status. Patients with HER2-positive patients are considered to be eligible for inclusion in this study; If the specimens provided are undetectable or are not available, a positive HER2 test from a local laboratory approved by the NMPA may be reported for entrainment.
   2. Previous treatment with two or more lines of anti-HER2 therapy, neoadjuvant therapy or adjuvant therapy can be used as a treatment line number if the disease progresses during or within 12 months after treatment.
   3. Evidence of investigator-confirmed or documented disease progression or intolerance of toxicity prior to enrollment.
3. The ECOG performance status must be 0 or 1.
4. Expected survival for at least 12 weeks.
5. Has adequate organ and bone marrow function: absolute neutrophil count (ANC) ≥ 1.0x1E9/L(without colony stimulating factor within 7 days); hemoglobin ≥ 90g/L (without red blood cell infusion within 14 days); platelet count ≥ 100x1E9/L(without thrombopoietin or thrombopoietin receptor agonists within 7 days nor platelet infusion within 14 days); Total bilirubin ≤ 1.5x upper limit normal (ULN), or ≤ 3x ULN if with Gilbert syndrome; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5x ULN; AST and ALT ≤ 5x ULN if liver metastasis; Serum creatinine \< 1.5x ULN and creatinine clearance ≥ 50mL/min (Cockroft-Gault formula calculation); Serum potassium ≥3.5 mmol/L；albumin ≥ 3g/dL; left ventricular ejection fraction (LVEF) \>50%；urinary protein ≤1+ or 24-hour urinary protein dose \< 1.0g.
6. Has at least one non-intracranial measurable lesion by RECIST version 1.1.
7. Male or female patients with fertility must agree to use effective contraceptive methods during the study period and within 3 months of the last dose of study therapy, such as dual barrier contraceptive methods, condoms, oral or injectable contraceptives, and intrauterine devices.
8. Ability to understand and voluntarily sign written informed consent.

Exclusion Criteria:

1. Patients who received chemotherapy, targeted therapy, radiotherapy, etc., 14 days or within 5 half-lives periods, whichever is shorter, prior to the start of dosing. Patients who received major surgery, tumor immunotherapy, or monoclonal antitumor therapy within 4 weeks prior to the start of dosing.
2. Patients who have participated in other clinical trials 4 weeks before the start of study drug administration or within 5 half-lives periods, whichever is shorter.
3. Patients previously treated with anti-HER2 ADC drugs.
4. Patients with central nervous system metastasis.
5. Clinically uncontrolled mass pleural effusion, pericardial effusion, or abdominal effusion (2 weeks before first administration).
6. Non-recovery of toxic effects from previous antitumor therapy (\> NCI-CTCAE 5.0 grade 1) alopecia, neurotoxicity, or other toxicity that had become chronic as assessed by the investigator and did not affect the safety of the investigational medication was admitted to NCI-CTCAE 5.0 grade 2 or below.
7. Patients with corneal epitheliopathy (other than mild punctiform keratopathy or existing eye diseases affecting the evaluation of ocular toxicity after trial administration) or who were unwilling to stop wearing contact lenses during the study.
8. Patients take medications that prolong the QTc interval (mainly Ia, Ic, Class III antiarrhythmic drugs) or have risk factors that prolong the QTc interval, such as uncorrectable hypokalemia, hereditary long QT syndrome;
9. Cardiac function and disease conform to one of the following conditions:

   1. Three 12-lead electrocardiogram (ECG) measurements were performed at the research center during the screening period, and three mean values were calculated according to the QTc formula adopted by the instrument, QTc \> 470 ms;
   2. New York Heart Association (NYHA)Grade ≥ 2 for congestive heart failure;
   3. arrhythmia of clinical significance grade ≥ 2.
   4. History of myocardial infarction or severe arteriovenous thrombosis within 6 months.
10. Pregnant or lactating women;
11. Known allergy to any excipients of FS-1502;
12. Active infections requiring systemic treatment;
13. Persons with active hepatitis B (HBV surface antigen positive with HBV DNA exceeding 1000 IU/ml or meeting the research Center criteria for diagnosis of active hepatitis B infection) or hepatitis C (HCV RNA positive), human immunodeficiency virus infection (HIV positive);
14. Had been diagnosed with any other malignancies within the 5 years prior to study participation, other than early malignancies that have undergone radical treatment (carcinoma in situ), such as adequately treated basal or squamous cell skin cancers or carcinoma in situ of the cervix;
15. Any other clinically significant disease or condition that the investigator believes may affect protocol compliance or affect the patient's signing of the ICF.

Primary outcomes:
measure: DLT of first single dose of FS-1502.
timeFrame: At the end of Cycle 1 (each cycle is 28 days or 21 days) in Phase Ia.
measure: MTD of single dose of FS-1502
timeFrame: At the end of Cycle 1 (each cycle is 28 days or 21 days) in Phase Ia.
measure: Recommend Phase 2 Dose(RP2D) of single dose of FS-1502
timeFrame: Throughout the Phase Ia
measure: Overall response rate (ORR) assessed by IRC
timeFrame: Approximately 2 years in Phase Ib.
Secondary outcomes:
measure: TEAE
timeFrame: Approximately 3 years.
measure: SAE and AE that leading to treatment permanent discontinuation
timeFrame: Approximately 2 years.
measure: Incidence of deaths and causes
timeFrame: Approximately 3 years.
measure: Progression free survival (PFS)
timeFrame: Approximately 2 years.
measure: Overall survival (OS)
timeFrame: Approximately 3 years.
measure: 1-year overall survival (OS) rate
timeFrame: 1 years
measure: Duration of response (DoR)
timeFrame: 2 years
measure: Clinical benefit response (CBR)
timeFrame: Approximately 2 years
measure: Area under the serum concentration versus time curve (AUC)
timeFrame: Approximately 2 years.
measure: Peak Serum Concentration (Cmax)
timeFrame: Approximately 2 years.
measure: Time to maximum concentration (tmax)
timeFrame: Approximately 2 years.
measure: Elimination half life (T1/2)
timeFrame: Approximately 2 years.
measure: Clearance (Cl)
timeFrame: Approximately 2 years.
measure: Anti-FS-1502 antibody
timeFrame: Approximately 2 years.
Other outcomes:
Locations:
city: Bengbu
country: China
facility: The First Affiliated Hospital of Bengbu Medical College
state: Anhui
city: Beijing
country: China
facility: Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
state: Beijing
city: Jilin
country: China
facility: Jilin Cancer Hospital
state: Changchun
city: Guangzhou
country: China
facility: Sun Yat-sen University Cancer Prevention Center
state: Guangdong
city: Meizhou
country: China
facility: Meizhou People's Hospital
state: Guangdong
city: Shenzhen
country: China
facility: Shenzhen Hospital, Cancer Hospital, Chinese Academy of Medical Sciences
state: Guangdong
city: Shijiazhuang
country: China
facility: The Fourth Hospital of Hebei Medical University
state: Hebei
city: Zhengzhou
country: China
facility: Henan Cancer Hospital
state: Henan
city: Wuhan
country: China
facility: Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
state: Hubei
city: Jinan
country: China
facility: Shandong Cancer Hospital
state: Shandong
city: Tianjin
country: China
facility: Tianjin Cancer Hospital
state: Tianjin
city: Hangzhou
country: China
facility: Run Run Shaw Hospital Affiliated to Medical College of Zhejiang University
state: Zhejiang
Study officials:
affiliation: Chinese Academy of Medical Sciences and Peking Union Medical College
name: BINGHE XU, PhD
role: PRINCIPAL_INVESTIGATOR
References: